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The enzyme CTP:phosphocholine cytidylyltransferase (CCT) is essential in
the lipid biosynthesis of Plasmodia (Haemosporida), presenting a promis-
ing antimalarial target. Here, we identified two independent gene duplica-
tion events of CCT within Apicomplexa and characterized a truncated
construct of Plasmodium falciparum CCT that forms a dimer resembling
the molecular architecture of CCT enzymes from other sources. Based on
biophysical and enzyme kinetics methods, our data show that the CDP-
choline product of the CCT enzymatic reaction binds to the enzyme con-
siderably stronger than either substrate (CTP or choline phosphate). Inter-
estingly, in the presence of Mg2+, considered to be a cofactor of the
enzyme, the binding of the CTP substrate is attenuated by a factor of 5.
The weaker binding of CTP:Mg2+, similarly to the related enzyme family
of aminoacyl tRNA synthetases, suggests that, with lack of Mg2+, posi-
tively charged side chain(s) of CCT may contribute to CTP accommoda-
tion. Thermodynamic investigations by isothermal titration calorimetry
and fluorescent spectroscopy studies indicate that accommodation of the
choline phosphate moiety in the CCT active site is different when it
appears on its own as one of the substrates or when it is linked to the
CDP-choline product. A tryptophan residue within the active site is identi-
fied as a useful internal fluorescence sensor of enzyme–ligand binding.
Results indicate that the catalytic mechanism of Plasmodium falciparum
CCT may involve conformational changes affecting the choline subsite of
the enzyme.
Database
Model data are available in the Protein Model DataBase (PMDB) under the accession number
PM0078718 (PfCCT(528–795)) and PM0078719 (PfCCT MDK)
Abbreviations
CDPCho, CDP-choline, cytidine 50-diphosphocholine; ChoP, choline phosphate or phosphocholine; CMP segment, functional domains of CCT
encompassing catalytic (C), membrane/lipid-binding (M) and putative phosphorylation (P) domains; CTP, cytidine triphosphate; ITC,
isothermal titration calorimetry; MESG, 2-amino-6-mercapto-7-methylpurine ribonucleoside; ML, maximum likelihood; PC,
phosphatidylcholine; PfCCT MDK, a truncated construct of PfCCT (PfCCT(528–795)D720–737 encompassing residues 528–795 without
the lysine-rich segment 720–737); PfCCT, Plasmodium falciparum CTP:phosphocholine cytidylyltransferase; PPi, pyrophosphate;
TCEP, (tris (2-carboxyethyl)phosphine).
3132 FEBS Journal 280 (2013) 3132–3148 ª 2013 FEBS
Structured digital abstract
● PfCCT MDK and PfCCT MDK bind by mass spectrometry studies of complexes (View interaction)
● PfCCT MDK and PfCCT MDK bind by comigration in gel electrophoresis (View interaction)
● PfCCT MDK and PfCCT MDK bind by molecular sieving (View interaction)
Introduction
Malaria continues to be a major world health problem
affecting a hundred million people annually, mostly in
African sub-Saharan countries. The disease is caused
by the infection and destruction of red blood cells by
protozoan parasites belonging to the genus Plasmo-
dium, Plasmodium falciparum and Plasmodium vivax
being the most widespread [1,2]. There is thus an
urgent need to identify new drug targets and develop
new pharmacophores with unique structures and mode
of action [3,4].
Successful growth and multiplication of the parasite
requires temporally controlled metabolic programmes
leading to duplication of the structural components.
The main Plasmodium membrane constituents are glyc-
erophospholipids produced by de novo pathways using
precursors that are actively transported from the host
cytoplasm [5,6]. Phosphatidylcholine (PC) is the major
phospholipid in P. falciparum membranes [7,8] and its
synthesis relies on numerous pathways, seldom found
together in a single organism [5,6]. Choline-mimicking
compounds arrest parasite growth with potent in vivo
antimalarial properties [9]. The clinical candidate albi-
tiazolium [10] that specifically inhibits de novo PC bio-
synthesis is structurally unrelated to existing
antimalarial agents and is currently being developed in
human phase 2 clinical trials for parenteral cures of
severe malaria [11].
De novo PC biosynthesis through the CDP-choline
(CDPCho) dependent Kennedy pathway is of crucial
importance in Plasmodium berghei [12] and P. falcipa-
rum. Within this pathway, the CTP:phosphocholine
cytidylyltransferase (2.7.7.15) enzyme [13–16] that
catalyses the second step of the CDPCho pathway by
condensing cytidine triphosphate (CTP) to phosphoch-
oline (ChoP) to obtain the energized CDPCho is rate
limiting and thus can be considered as a potential
molecular drug target.
The CCT genes are annotated in different Plasmo-
dium genomes as unique copies. Surprisingly, the plas-
modial CCT genes encode two putatively duplicated
CCT segments (abbreviated as CMP segments), each
including a cytidylyltransferase catalytic domain (C1/
C2), a membrane/lipid binding domain (M1/M2) and
a putative phosphorylation domain (P1/P2). Between
the two CMP segments, there is a long linker (240–278
amino acids), which is partially conserved. Other
known CCTs possess a single catalytic domain and
also one copy of the membrane binding and phosphor-
ylation domains, and are reported to form homodi-
mers in solution [17]. Hence, the two duplicated
segments of plasmodial CCT proteins might associate
to form an intramolecular ‘pseudo-dimer’, although
this suggestion has not yet been investigated experi-
mentally. It has been shown that a recombinant P. fal-
ciparum CCT protein construct (PfCCT528–896)
containing the second catalytic domain (C2) followed
by the membrane interaction domain (M2) is enzymat-
ically active [18].
CCT expression is apparent in all life stages of Plas-
modium [11,19]. Microarray data (PlasmoDB) [20]
show a transcription increase in late schizonts and sig-
nificant transcription in gametocytes and sporozoites
as well. Membrane interaction of an amphipathic seg-
ment of the membrane binding domain (M) regulate
CCT enzymatic activity while removal of the mem-
brane binding segment from the CCT protein results
in a constitutively active enzyme [21]. For the rat CCT
enzyme, an in vitro kinetic study suggested random
mechanism for binding and release of the substrates/
products, with Michaelis constant KM values of
10 mM and 0.3 mM for CTP and ChoP, respectively
[22].
Although CCT activity is crucial for Plasmodia at
their blood stage, the enzyme:substrate binary com-
plexes have not yet been investigated in detail. To
date, no three-dimensional structure of any CCT:sub-
strate complex is available. Current structural con-
cepts rely on the three-dimensional CCT:CDPCho
structure of the rat catalytic domain (PDB ID 3HL4)
[23] and structures of other cytidylyltransferase:
nucleotide complexes (ECT:CMP and GCT:CTP,
PDB IDs 3ELB and 1COZ, respectively) [24]. It is
also not known whether binary CCT:substrate com-
plexes already adopt a catalytically competent confor-
mation or such conformation is reached only in the
ternary complex of the enzyme with the two sub-
strates.
In the present study, we investigated the evolution-
ary origin of the two domains and the catalytic mecha-
nism and ligand binding properties of PfCCT. We
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reconstructed the most likely evolutionary scenario
that led to the duplication of the CMP segments in
CCT within Apicomplexa. We then designed and char-
acterized a catalytic domain construct of PfCCT using
the C2 catalytic domain, and showed that this con-
struct is enzymatically functional and forms a dimer,
similarly to other CCTs. We constructed a three-
dimensional structural model of this enzyme and used
a continuous spectrophotometric method to monitor
its steady-state kinetic behaviour. Binding of substrates
and products was followed by fluorescence
spectroscopy and isothermal titration calorimetry
(ITC). Relying on a Trp fluorophore located in the
active site, we could characterize alterations in the
binding modes of substrate and product containing
the choline moiety. Thermodynamic analysis revealed
that the presence of Mg2+, the cofactor of CCT catal-
ysis, attenuates the binding of CTP. Taken together,
the present ligand binding and kinetic studies of the
enzyme contribute to the understanding of the cata-
lytic mechanism of PfCCT.
Results
Phylogenetic analyses revealed two independent
duplication events of CMP segments in CCTs
within Apicomplexa
The CCT catalytic domain (C) is widely conserved
from plants to animals. Putative CCT enzymes har-
bouring duplicated C domains are found only in three
Apicomplexan parasites, Plasmodium, Babesia and
Theileria, within the class Aconoidasida. Sequence
alignment revealed that the duplicated C domains of
plasmodial CCT are highly identical (Fig. 1). This can
be exemplified with PfCCT, showing 90% sequence
identity and 97% similarity between the N- and the
C-terminal catalytic domains (C1 and C2, respec-
tively). To reconstruct the history of duplication events
that led to the existence of duplicated CCT genes in
Apicomplexa, we performed a phylogenetic analysis.
The alignment of the full CCT protein sequences is
presented in Fig. S1. It shows that the single CMP seg-
ment observed in Coccidia (Cryptosporidium, Neospora
and Toxoplasma) is homologous to the N-terminal seg-
ment of Aconoidasida (other genera). The maximum
likelihood (ML) tree obtained for the 16 full Apicom-
plexan CCT proteins is shown in Fig. 2A. The phylo-
genetic relationships among the Apicomplexan species
included are fully compatible with the tree recently
inferred from genome-scale data [25]. Indeed, Babe-
sia microti also appears as a distinct lineage that
diverged early within Piroplasmida, rendering the
genus Babesia paraphyletic. It should also be noted
that Piroplasmida members are particularly fast evolv-
ing compared with all other Apicomplexans.
The ML tree inferred for the 27 CMP protein seg-
ments of Apicomplexan CCTs is presented in Fig. 2B.
By reconstructing the CMP segment duplication his-
tory during the evolution of Apicomplexa, this phylog-
eny allows the hypothesis of a single ancestral
duplication of a CMP segment in the CCT gene pre-
dating the separation between Piroplasmida (Babesia
and Theileria) and Haemosporida (Plasmodium) to be
tested [5]. In this hypothetical scenario, N-terminal
and C-terminal segments are predicted to form distinct
monophyletic subtrees whose internal relationships
should exactly mirror the species tree of Fig. 2A. The
ML tree in Fig. 2B clearly shows that this is not the
case. Indeed, the sequences of the duplicated C-termi-
nal segments fall into two distinct monophyletic
groups, each being closely related to a cluster of N-ter-
minal sequences within both Piroplasmida and Hae-
mosporida. The most likely scenario to explain such a
phylogenetic pattern is that two independent domain
duplication events occurred in the last common ances-
tor of Piroplasmida on one side and Haemosporida on
the other side. Moreover, the large difference observed
in sequence divergence between the N-terminal and
C-terminal segments in Piroplasmida and Haemospori-
da suggests that these two independent duplications
have occurred at different points in time. Indeed, the
high degree of sequence divergence observed among
the duplicated segments in Babesia and Theileria spe-
cies might be explained by a duplication event early in
the evolutionary history of Piroplasmida. Conversely,
the high similarity of duplicated CMP segments
observed between Plasmodium species may be the
result of a more recent duplication event in the Hae-
mosporida lineage. Based on this evolutionary scenario
resulting in two very similar catalytic domains of
PfCCT and due to the fact that full-length PfCCT
could not be expressed and purified for biochemical
analysis so far, we decided to study one of the PfCCT
catalytic domains as a model.
Homology model and characterization of the
PfCCT catalytic domain
A homology model of the two catalytic domains of
PfCCT was built based on the published structure of
the homodimer catalytic domain of rat CCT (see Sup-
porting information) [23]. Analysis of these models
shows that neither of the very few residues that differ
in C1 and C2 is bordering the conserved active site of
the enzyme. The high degree of sequence identity
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between the two catalytic domains of PfCCT probably
allows one single domain to dimerize as in other stud-
ied CCTs. We engineered a truncation construct
(PfCCT528–795) that contains the C2 catalytic domain
but does not contain the membrane-binding M2
domain and is therefore expected to be constitutively
active. A lysine-rich region (residues 720–737, termed
as K-loop in Fig. 3A), constituting a species-specific
insertion in Plasmodia sequences, was removed to aid
purification of the recombinant construct (see Materi-
als and methods). Comparing homology models either
containing or lacking this lysine-rich segment revealed
no structural differences affecting the folding of the
catalytic domain (compare models in wheat and blue-
white colours in Fig. 3A). The construct PfCCT
(528–795)D720–737 lacking the lysine-rich segment
(abbreviated as PfCCT MDK) was expressed in
Escherichia coli. Removal of the lysine-rich segment
improved the thermal stability of the PfCCT construct
as judged by an ~ 9 °C increase in melting temperature
(Tm), measured by differential scanning fluorimetry
(Fig. S2).
Fig. 1. Residue conservation pattern
within duplicated CCT catalytic domains in
Apicomplexa. Alignment of
cytidylyltransferase catalytic domain
sequences, whose boundaries are
identified by the PFAM server [56]. RAT,
Rattus norvegicus CCT (Uniprot entry
P19836), (residues 80–208); TOXGO,
Toxoplasma gondii (B6KSU6) (54–203);
PLAF7, Plasmodium falciparum 3D7 strain
(Q8IEE9) (36–182 and 621–767); PLABA,
Plasmodium berghei (Q4YBQ9) (29–183
and 588–736); BABMI, Babesia microti
(I7I8D8) (16–160 and 314–510); BABBO,
Babesia bovis (A7AU63) (10–158 and 323–
448); THEAN, Theileria annulata (Q4UFG5)
(1–131 and 267–394); THEPA,
Theileria parva (Q4N412) (13–150 and
286–413). The alignment was initially
performed by CLUSTALW and then manually
adjusted. Residues conserved among the
cytidylyltransferase superfamily (GCT,
ECT, CCT enzymes) are highlighted with
white letters on a dark grey box; residues
conserved among CCT enzymes are
highlighted with a light grey box. The
positions of the W residues within the
PfCCT sequences are shown by grey and
black arrows, the latter indicating the
conserved W residue bordering the active
site.
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We used in silico analysis of structural disorder
(Fig. 3B) to assess further structural characteristics.
Within the full-length CCT sequence, there are numer-
ous highly flexible/disordered segments in the linker
region connecting the two duplicated segments. The
lysine-rich segment is present in both C1 and C2
A B
Fig. 2. Phylogenetic analyses of domain duplication within Apicomplexa parasites. (A) ML phylogenetic tree of the 16 full-length CCT
Apicomplexan proteins. Numbers at nodes are bootstrap percentages with bullets indicating a value of more than 95. The scale is in mean
number of substitutions per site. Structures of the CCT gene with location of CMP segments in the main Ampicoplexan groups are
represented following Dechamps et al. [5]. (B) ML phylogenetic tree of the 27 CMP protein segments of the CCT gene in Apicomplexa.
Numbers at nodes are bootstrap percentages, bullets indicating a value of more than 95. The scale is in mean number of substitutions per
site. Nodes without numbers have bootstrap percentages < 70. D1 and D2 indicate the two independent duplication events required to
explain the inferred phylogenetic pattern.
A B
Fig. 3. Structural model of the PfCCT MDK construct. (A) Superimposed homology models of the homodimer forms of the PfCCT MDK
(528–795)D720–737 construct (shown in cartoon model, coloured blue-white) and the PfCCT(528–795) construct (shown in cartoon model,
coloured wheat) containing the C2 domain are superimposed. The models were built with the MODELLER program using the rat CCT crystal
structure (PDB ID 3HL4) as template. The CDPCho ligand is shown as sticks, using atomic colouring (carbon, yellow; oxygen, red;
phosphorus, orange; nitrogen, blue). The tryptophans W682, W692, W743 are shown as sticks, coloured blue. (B) Disorder profile of full-
length PfCCT. The plot shows the probability of disorder predicted by RONN [57], IUPRED [58] and DISOPRED [59]. C1 and C2 domains, coloured
green, were classified as ordered by all three predictors. The lysine-rich segments (K, coloured cyan) within the ordered conserved catalytic
domains are predicted to be highly flexible.
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domains and is predicted to possess high disorder. The
region encompassing residues 540–610, present within
our engineered PfCCT MDK construct, is also pre-
dicted to possess high flexibility/disorder.
Gel filtration of PfCCT MDK under native condi-
tions resulted in a single peak, at an elution volume
corresponding to a molecular mass of approximately
268 kDa (Fig. S3), which is unexpectedly high (for
comparison, the molecular mass of the PfCCT MDK
polypeptide calculated from the amino acid sequence
is 30.9 kDa). Denaturing SDS/PAGE analysis revealed
that this peak contains one polypeptide component for
which the apparent molecular mass based on SDS/
PAGE analysis is estimated to be 37 kDa (Fig. 4A),
again considerably higher than the calculated molecu-
lar mass of 30.9 kDa. SDS/PAGE and gel filtration
data therefore indicate anomalous migration of the
protein in gel electrophoresis and possible formation
of higher oligomers under native conditions. The pres-
ence of flexible segments as suggested by the disorder
predictors (Fig. 3B) may explain this behaviour and
also suggests that estimation of the oligomerization
status of the native molecular mass of this protein
based on size exclusion chromatography is not reliable,
since deviations from the ideally expected hydrody-
namic behaviour of globular proteins are expected to
greatly perturb elution characteristics.
To investigate the oligomerization state of PfCCT
MDK, we therefore performed electrospray ionization
mass spectrometry, which has been shown to provide
valuable data on protein–protein complexation [26].
The electrospray mass spectrum of PfCCT MDK
under native conditions (Fig. 4B) reveals two abun-
dant ion series in the mass range m/z 1900–4000. In
the upper mass range (m/z 3000–4000), peaks corre-
sponding to a dimer structure can be observed. The
charge state distribution is rather narrow, encompass-
ing mainly z = +18 to z = +20 ions, indicating that the
native protein conformation survives the transfer from
solution to the mass spectrometer [27]. The molecular
mass of the dimer was determined to be
61 840  200 Da (cf. the calculated dimer molecular
mass of 61.8 kDa). At the lower mass range (m/z
1900–3000), the ion series corresponding to the mono-
mer form is present. The charge distribution is centred
on the +13 ions, and the mass calculated from the dis-
tribution is 30 870  200 Da, in very good agreement
with the calculated molecular mass. Based on the inte-
grated peak areas, a monomer : dimer ratio of 10 : 13
was estimated. Signals due to higher oligomers – tri-
mer, tetramer etc. – are practically unobservable, set-
ting an upper limit of 3% for their relative abundance
on the basis of the signal to noise ratio. The preference
for dimer formation suggests that the dimer structure
reflects the association existing in solution, i.e. it is not
due to non-specific aggregation upon ionization.
Dimerization of the PfCCT MDK construct is also
suggested by the three-dimensional structural model
and is in agreement with the oligomer properties of
other CCT enzymes.
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Fig. 4. PfCCT MDK is predominantly present in homodimer form in solution. (A) Purification steps of PfCCT MDK followed by 12% SDS/
PAGE: lane 1, molecular mass standards; lane 2, E. coli extract; lane 3, sample eluted from Ni affinity purification; lane 4, sample after gel
filtration. (B) Mass spectrum of PfCCT MDK protein under native electrospray conditions. M and D denote monomer and dimer signals,
respectively, whereas numbers indicate the charge states. The two insets are enlarged graphs for the monomer and dimer ion series
regions, with determined molar masses 30 870 (200) Da and 61 840 (200) Da, respectively.
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Random order kinetic mechanism shown by
steady-state analysis
The enzymatic properties of the PfCCT MDK con-
struct were determined by using a continuous spectro-
photometric assay [28] that was adopted for other
pyrophosphate producing enzymes [29,30]. Substrate
titrations with CTP and ChoP were performed while
the other substrate was added at saturating concentra-
tion. A plot of the initial rate as a function of CTP
concentration provided a saturation curve (see
Fig. 5A), which fits the Michaelis–Menten equation
providing the apparent kinetic parameters 1.45 
0.05 s1 for the turnover number kcat and 168 
17 lM for KM,CTP (Table 1). In the ChoP titration,
we observed substrate inhibition at [ChoP] > 5 mM.
The ChoP titration data were fitted with a substrate
inhibition equation (shown in Materials and methods)
providing an apparent KM,ChoP of 1.8 mM (Fig. 5B).
As a consequence, in the CTP titration experiment,
ChoP was used at a sub-inhibitory concentration of
5 mM. None of the CTP and ChoP substrate satura-
tion data showed significant cooperativity, as judged
by the Akaike information criterion test comparing the
Michaelis and Hill fitted models. Deletion of the
A B
C1
D1
C2
D2
Fig. 5. Steady-state kinetic analysis of the
PfCCT MDK catalysed reaction in the
absence and presence of CDPCho
product. (A) CTP titration of PfCCT MDK at
a fixed ChoP concentration of 5 mM. The
plot shows one representative experiment.
Titration data are fitted with the Michaelis–
Menten kinetic model assuming no
cooperativity. (B) ChoP titration of PfCCT
MDK at a fixed CTP concentration of
900 lM. The plot shows one
representative experiment. Titration data
are fitted with a kinetic model assuming
substrate inhibition without cooperativity.
Note the substrate inhibition effect of
ChoP as an initial rate decrease is
observed at higher substrate
concentrations. (C1) CTP titration curves
for PfCCT MDK with addition of CDPCho
at different concentrations. The
concentration of ChoP was fixed at 5 mM.
Global fit of the titration data is shown
with the full competitive inhibition model
(Eqn 5), yielding Ki, as indicated in the
text. (D1) ChoP titration curves for PfCCT
MDK with addition of CDPCho at different
concentrations. The concentration of CTP
was fixed at 900 lM. For C1 and D1
Lineweaver–Burk plots are also shown (C2
and D2).
Table 1. Kinetic parameters of PfCCT MDK catalysis. Kinetic parameters were obtained as described in Materials and methods. One
enzyme unit (U) is the number of nanomoles of CDPCho produced per minute.
CTP titration ChoP titration
Vmax (Umg1) kcat (s1) KM,CTP (lM) kcat (s1) KM,ChoP (mM) KI,ChoP (mM)
2810 1.45  0.05 168  17 1.2  0.4 1.8  1.1 10.5  7.5
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lysine-rich segment did not modify enzyme activity
(data not shown).
In order to assess the binding order of the substrates
CTP and ChoP, we performed a kinetic analysis based
on CDPCho product inhibition. The initial rate of the
CCT reaction was measured as a function of either
substrate while the concentrations of the other sub-
strate and the CDPCho product were kept constant
(Fig. 5C,D). We found that the inhibitory pattern of
CDPCho showed a major competitive character with
respect to both CTP and ChoP substrates, which can
be interpreted within the framework of a random bi–bi
mechanism [31]. The apparent inhibition constant Ki
of CDPCho is estimated from the fit to be 65 lM.
Comparison of the heat effects of substrate and
product binding at the choline subsite
Since ITC is an especially useful technique for quanti-
tative characterization of biological interactions, we
used it to obtain thermodynamic parameters of the
binding of substrates and products to PfCCT MDK.
Titration calorimetry experiments were performed in
the same buffer as was used in the activity assay,
including 5 mM Mg2+ (Fig. 6A–D, Table 2).
For both CTP and CDPCho titration of PfCCT
MDK (Fig. 6A,D), the best fit to the experimental
data was obtained by fitting a one-site independent
binding model. This, together with the observed stoi-
chiometry close to the ratio 1 : 1, is consistent with
the kinetic titration data (Table 2). The binding of
these ligands to the enzyme did not show any signifi-
cant cooperativity under our experimental conditions.
In the case of the CDPCho product, the dissociation
constant Kd of 89 lM is in good agreement with the
inhibition constant Ki of 65 lM determined in the
steady-state experiments. The CTP equilibrium ligand
binding experiment reports similar affinity
(Kd = 294 lM) to the value of the respective Michaelis
constant (KM = 168 lM). Both CDPCho and CTP
ligands exhibited negative binding enthalpy and
entropy values, which indicate that binding of the
ligands is enthalpically favoured and entropically disfa-
voured. The latter observation for CTP binding is con-
sistent with previous NMR data of CTP binding to
GCT, a related cytidylyltransferase enzyme [32]. Nev-
ertheless, CDPCho binding to the enzyme occurs with
more than twofold higher enthalpy compared with
CTP binding, shedding light on the potentially differ-
ent interactions with these two ligands. These could be
due to either different accommodation of the pyro-
phosphate group of CTP and the b phosphate group
of CDPCho and/or the contribution of the interactions
of the trimethylammonium moiety of CDPCho at the
choline binding subsite in the active site of CCT.
Titration of the enzyme with pyrophosphate (PPi)
product yielded only minor heat effects (Fig. 6C).
These calorimetric signals may be interpreted by esti-
mating that the dissociation constant of the CCT:PPi
complex is in the millimolar range. On the other hand,
we could not measure any significant calorimetry signal
of apo PfCCT MDK enzyme for ChoP titration (up to
2 mM, already above the KM determined in the kinetic
assay) (Fig. 6B). This result indicates that either ChoP
binding to the apoenzyme does not occur under these
conditions or the enthalpic character of this binding is
negligible when ChoP is present on its own.
In order to reveal any indirect effect of ChoP bind-
ing, we applied the displacement ligand titration
method that has been shown to be effective in detect-
ing ligand binding events with low millimolar affinities
[33]. Immediately following the ChoP titrations, the
PfCCT MDK solutions containing ChoP were further
titrated with CDPCho to assess an equilibrium ligand
displacement titration of ChoP to CDPCho. These
subsequent product titrations yielded thermodynamic
parameters very similar to those obtained from apo
PfCCT MDK CDPCho titrations in the absence of
ChoP (Fig. 6I,J, Table 2). Hence, the results did not
show any detectable binding of ChoP suggesting that
under our experimental conditions ChoP binding to
the apoenzyme cannot be observed and arguing for a
lower limit of the dissociation constant Kd,ChoP
> 5 mM (to be compared with a KM of 1.8 mM).
Mg2+ attenuates enzyme affinity towards CTP
Mg2+ is reported to be required for CCT catalysis
[18,34,35]; therefore Mg2+ is a generally used additive
in CCT assay conditions. However, no data are avail-
able on its effect on ligand binding to the enzyme. We
therefore carried out a set of ITC experiments in the
absence of added Mg2+ (Fig. 6E–H). Titration of the
enzyme with CDPCho showed similar thermodynamic
parameters in the absence and presence of Mg2+ co-
factor (with dissociation constants 44 and 89 lM,
Fig. 6D,H, respectively). CTP affinity, in contrast,
seems to be strongly dependent on the presence of the
metal cofactor. Addition of 0.5 mM EDTA resulted in
significantly higher affinity of the enzyme towards
CTP than in the presence of Mg2+ (the observed dis-
sociation constant being 59.5 lM compared with
294 lM, respectively) (Fig. 6A,E, Table 2). ChoP titra-
tion and PPi titration provided practically the same
results in the absence as well as in the presence of
Mg2+ (Fig. 6B,C,G,H).
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Intrinsic fluorescent signal points to differences
between ChoP and CDPCho bound states of the
enzyme
In order to gain information on the microenvironment
of the active site, we investigated the change in the
intrinsic Trp fluorescence signal. PfCCT MDK has
three tryptophan residues: W682, W692 and W743
(Fig. 1). W682 is buried at the dimer interface while
the other two residues are more solvent-accessible;
W743 is part of the aL-helix, located on the construct
surface (Fig. 3A), while W692 establishes a cation–p
interaction with the trimethylammonium moiety of the
CDPCho product at the active site (Figs 3A and 7)
[23]. To identify the Trp residue that is responsible for
the observed signal changes, we created two constructs
by site-directed mutagenesis, performing a W/H
exchange at position 743 and a W/Y exchange at posi-
tion 692, respectively. The PfCCT MDKW743H showed
similar ligand binding (Fig 6K, Table 2) and catalytic
properties, whereas for the PfCCT MDKW692Y mutant
the interaction with CDPCho is still present but
becomes somewhat perturbed (Fig 6L, Table 2, Kd
increases threefold).
Addition of CDPCho led to an increase in the inten-
sity of the intrinsic Trp fluorescence signal of PfCCT
MDK (Fig. 8A). Moreover, the fluorescence emission
maximum shifted from 347.7 to 344.2 nm. Plotting the
emission maximum shifts (kmax) against CDPCho con-
centration resulted in a saturation curve, indicating
saturation of enzyme active sites with CDPCho
(Fig. 8B). The dissociation constant of PfCCT MDK
Table 2. Thermodynamic parameters of ligand binding to PfCCT MDK constructs determined by direct and displacement titrations at 20 °C.
PfCCT construct Mg2+ N Kd (lM) DH (kcalmol1) DS (calmol1K1)
MDK CDPCho 5 mM 0.88  0.03 88.5  7.2 24.0  1.0 63.3  19.0
MDK CTP 5 mM 0.62  0.01 294  4.0 9.6  1.7 16.6  3.6
MDK CDPCho (5 mM ChoP present)a 5 mM 0.85  0.01 88.5  3.4 23.2  0.4 60.5  2.5
MDK CDPCho None 0.57  0.02 44.4  3.3 22.9  1.0 58.1  5.0
MDK CTP None 0.96  0.02 59.5  1.8 8.6  0.3 10.1  0.5
MDK CDPCho (2 mM ChoP present)a None 0.75  0.01 42.9  0.8 20.7  0.1 50.7  1.0
MDKW743H CDPCho None 0.96  0.01 67.7  0.9 13.5  0.1 27.0  0.4
MDKW692Y CDPCho None 0.83  0.24 218  50 9.8  4.5 16.8  8.6
a Displacement titrations.
CDPCho
K663
W692
Fig. 7. Active site close-up of the PfCCT MDK model with bound
CDPCho product. CDPCho is shown as sticks with atom colouring
(carbon, yellow; oxygen, red; phosphorus, orange; nitrogen, blue).
Residue side chains coordinating the CDPCho are shown as sticks
coloured by element (carbon, grey; oxygen, red; phosphorus,
orange; nitrogen, blue). Note W692 establishing a cation–p
interaction with the trimethylammonium moiety of CDPCho.
Fig. 6. Equilibrium ligand binding to PfCCT constructs followed by ITC. (A) Titration of 301 lM PfCCT MDK (monomer concentration) with
9 mM CTP in the presence of 5 mM Mg2+. (B) Titration of 257 lM PfCCT MDK with 30 mM ChoP in the presence of 5 mM Mg2+. (C)
Titration of 257 lM PfCCT MDK with 10 mM PPi in the presence of 5 mM Mg
2+. (D) Titration of 219 lM PfCCT MDK with 3.5 mM CDPCho in
the presence of 5 mM Mg2+. (E) Titration of 360 lM PfCCT MDK with 7.5 mM of CTP in the presence of 0.5 mM EDTA. (F) Titration of
329 lM PfCCT MDK with 12 mM ChoP. (G) Titration of 356 lM PfCCT MDK with 10 mM PPi. (H) Titration of 146 lM PfCCT MDK with
2.0 mM CDPCho. (I) Titration of 257 lM PfCCT MDK with 3 mM CDPCho in the presence of 5.0 mM ChoP and 5 mM Mg2+. Note that the
presence of 5.0 mM ChoP has no effect on the binding characteristics of CDPCho (cf. D). (J) Titration of 329 lM PfCCT MDK with 3.0 mM
CDPCho in the presence of 2.0 mM ChoP. Note that the presence of 2.0 mM ChoP has no effect on the binding characteristics of CDPCho
(cf. H). (K) Titration of 165 lM PfCCT MDKW743H with 3.0 mM CDPCho. (L) Titration of 179 lM PfCCT MDKW692Y with 2.5 mM CDPCho.
Integrated heat curves were corrected by subtracting the heat of dilution.
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with the CDPCho complex was found to be
19.2  2.4 lM, which is in adequate agreement with
the value of 44  2 lM determined by ITC (Table 2).
Titration of PfCCT MDK with the ChoP substrate is
not accompanied by either an increase of fluorescence
intensity or a blue shift of the fluorescence emission
maximum (Fig. 8B). For the PfCCT MDKW743H
mutant, titration with CDPCho resulted in a similar
intensity increase and a shift of the emission maximum
compared with the wild type, with an observed binding
constant of 32.4  5.8 lM (Fig. 8B). In contrast, no
such fluorescence signal change was observed upon
titration of PfCCT MDKW692Y with CDPCho
(Fig. 8B). We conclude that the changes of fluorescent
emission spectral parameters induced by binding of
CDPCho to the enzyme are due to the W692 residue
present within the active site.
Discussion
Here we report a detailed ligand binding and kinetic
study of a truncated construct of PfCCT (PfCCT
MDK) that contains a single catalytic domain but
lacks the membrane binding domain. To evaluate com-
patibility of the construct with the full-length PfCCT
sequence, we investigated the conservation pattern of
the duplicated CMP segments in Apicomplexa. Results
of the phylogenetic analyses indicate two independent
ancestral gene duplication events in Haemosporida
(Plasmodia) and Piroplasmida, the former having
occurred more recently. This indicates a reduced possi-
bility for the functional divergence of the C1 and C2
domains. Widespread sequence conservation and the
rat CCT crystal structure [23] enabled the creation of
a homology model of the investigated PfCCT con-
struct containing the C2 domain. These considerations
together with the present results indicating dimeriza-
tion and the steady-state kinetic characteristics of
PfCCT MDK verify that this construct constitutes a
reliable catalytically functional model for the physio-
logically expected C1/C2 pseudo-heterodimer catalytic
domain assembly of full-length PfCCT.
The observed competitive inhibition pattern of
CDPCho versus the two substrates indicates that
CDPCho can bind to the same enzyme conformation
as either substrate. Interpretation of our product inhi-
bition measurements in the light of the above consider-
ations suggests a random binding mechanism for
PfCCT MDK, in agreement with previous data for rat
CCT [22]. In such a kinetic mechanism, either sub-
strate (CTP or ChoP) can bind to the apoenzyme on
its own. However, in our ligand binding experiments
based on either fluorescence spectroscopy or ITC, no
binding of ChoP to the apoenzyme could be observed,
in contrast to the suggested kinetic mechanism. It has
to be emphasized that both techniques could be used
with success to follow binding of CDPCho to the apo-
enzyme, and although fluorescence spectroscopy is an
indirect method ITC is considered to be a generally
applicable direct technique to evaluate molecular inter-
A B
Fig. 8. Equilibrium CDPCho binding to PfCCT MDK constructs by Trp fluorescence. (A) Emission spectrum of PfCCT MDK in the absence of
ligands (line without symbols) and in the presence of 100 lM CDPCho (line with full circles). Note the intensity increase and the blue shift
upon CDPCho addition. (B) Equilibrium binding titration experiments of PfCCT MDK and its point mutants with CDPCho. The shift of the
emission maximum in the presence of different amounts of ligand was analysed by fitting the Gauss peak function to the emission
spectrum (see Materials and methods). PfCCT MDK titrations with CDPCho and ChoP are shown as full and open circles, respectively.
Titrations of PfCCT MDKW743H and PfCCT MDKW692Y with CDPCho are shown as full triangles and full diamonds, respectively. Note the
absence of the emission maxima shift upon ChoP titration.
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actions. To reconcile the data from the kinetic and
ligand binding experiments, it is important to realize
that kinetic studies have their own limitations as well.
Accordingly, it was shown that an observed kinetic
pattern for the random mechanism may not identify
the relevant set of elementary steps [36].
The fluorimetric titrations in our study rely on the
signal of W692, located in the choline subsite of the
active site. The homology model reveals that this resi-
due possibly monitors CDPCho binding to the active
site by juxtaposing the trimethylammonium moiety of
CDPCho to the indole ring of W692 (Fig. 7). The lack
of any fluorescent signal upon ChoP addition is proba-
bly due to a different microenvironment of the choline
subsite. ITC experiments also including displacement
ligand titrations reported considerable heat effects for
CDPCho binding, whereas no such heat effects were
found for ChoP, strengthening the suggestion that the
interaction of the ChoP moiety with the choline bind-
ing subsite in the enzyme depends on whether ChoP is
present on its own or within CDPCho.
Mg2+ was reported to be a cofactor of cy-
tidylyltransferases [35]; however, we found that CTP
and CDPCho bind to the CCT enzyme even in the
absence of Mg2+ (cf. Fig. 6C,F). This correlates well
with successful co-crystallization of enzymes belonging
to the cytidylyltransferase family with CDPCho and
CTP in the absence of Mg2+ [23,24]. Moreover, we
also observed that addition of Mg2+ significantly
decreased the binding affinity of CCT towards CTP.
In the absence of the divalent cation, binding of the
nucleotide needs to be accomplished by adequate
charge compensation of the phosphate chain, presum-
ably performed by positively charged and polar resi-
dues. Considering the sequence conservation within
the catalytic domain of CCTs as well as the structural
models, residues R755 and K663 as well as T761 and
T762 [37] may be proposed to fulfil such coordinating
roles for the phosphate chain. We propose that Mg2+
may be important for efficient catalysis but not for
nucleotide binding for CCT enzymes belonging to the
HxGH enzyme superfamily [38]. Lack of requirement
for Mg2+ during nucleotide binding to the enzyme
may also present a possible mode of action in the
HxGH enzyme superfamily. Such a situation was
experimentally verified for a class I aminoacyl tRNA
synthetase that binds its cognate nucleotide ATP with
considerably higher affinity in the absence rather than
in the presence of Mg2+ [39].
In our study, we delineated the possible evolutionary
steps leading towards Plasmodia CCT proteins, identi-
fied a useful fluorophore within the active site of CCT
and provided insights into kinetic and ligand binding
characteristics of a PfCCT construct that can be
expressed and purified for detailed studies. Based on
these results, further research directions are suggested
to focus on a detailed in-depth kinetic study of the ele-
mentary steps of CCT catalysis and on generating
experimental three-dimensional structures to provide a
full coherent knowledge of the mechanism of action of
this important enzyme.
Materials and methods
Chemicals
Restriction enzymes, T4 DNA ligase, DNA polymerases and
DNA purification kit were obtained from Machenary-Nagel
(Du¨ren, Germany). CTP, CDPCho, Sypro Orange, inorganic
pyrophosphatase, purine nucleoside phosphorylase and anti-
biotics were purchased from Sigma-Aldrich (St Louis,
MO, USA). ChoP was from TCI Europe N.V. (Antwerp,
Belgium).
Isopropyl thio-b-D-galactoside was obtained from Fisher
Scientific GmbH (Schwerte, Germany). MESG (2-amino-
6-mercapto-7-methylpurine ribonucleoside) was obtained
from Berry and Associates (Dexter, MI, USA). Nickel-
nitrilotriacetic acid was from Qiagen (Du¨sseldorf, Ger-
many), protease inhibitor cocktail tablets were purchased
from Roche (Basel, Switzerland). All other chemicals were
of analytical grade of the highest purity available.
Phylogenetic analyses
A first data set containing the amino acid sequences of
CCT proteins was assembled from GenBank for 16 Api-
complexan taxa including species belonging to the genera
Crytosporidium, Neospora, Toxoplasma, Babesia, Theileria
and Plasmodium. These full-length protein sequences were
aligned using the probabilistic consistency-based program
PROBCONS [40] with default parameters on the Phylogeny.fr
portal [41]. This resulted in an alignment with 1122 amino
acid sites. In order to reconstruct the history of domain
duplication within these proteins, a second data set was
constructed by extracting the regions of the full alignment
corresponding to the N-terminal and C-terminal CMP seg-
ments, leading to 16 and 11 sequences, respectively. Indeed,
only members of the genera Babesia, Theileria and Plasmo-
dium possess a duplicated C-terminal domain, whereas Cry-
tosporidium, Toxoplasma and Neospora exhibit a CCT gene
with a single CMP segment. The amino acid sequences of
the 27 extracted domains were realigned using the phylog-
eny-aware PRANK program on the webPRANK server [42]
with default parameters. This resulted in a final alignment
with 362 sites.
Ambiguously aligned sites were subsequently removed
from both data sets using the GBLOCKS program [43] with
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default relaxed parameters. This led to final alignments
with 456 and 217 amino acid sites for the full gene and
domain data sets, respectively. ML phylogenetic reconstruc-
tion was conducted on these two data sets using PHYML 3.0
[44] with NNI branch swapping on a BIONJ starting tree.
For both data sets, the LG+G4 model of protein sequence
evolution was selected as the best fitting model by PROTTEST
3 [45]. The statistical robustness of phylogenetic infer-
ence was assessed by performing 100 bootstrap replicates
using the same heuristic search strategy as for the initial
analyses.
Homology modelling
Homodimer homology models have been built for
constructs PfCCT(528–795) and PfCCT MDK using the
catalytic domain of the rat CCT which included the
CDPCho product (PDB ID 3HL4) [23]. Both homology
models were built using the same computational proce-
dure. The alignment previously published in the literature
[23] was slightly modified in the neighbourhood of the
lysine-rich segment. The identity of the alignment was
42.21%. For homology modelling only residues 581–775
were considered, as in the rat CCT X-ray structure no
template was found for the starting and end sequences of
the construct. The MODELLER 9v8 software [46] was used
to create 100 homology models for both constructs using
the same alignment. The low energy conformations with
low objective function values were visually inspected and
one with appropriately coordinated CDPCho ligand was
selected for each construct. The selected structures were
optimized with CHARMM27 force field [47] and CHARMM
software [48] using the GBSW implicit solvent model.
The topology file and non-standard parameters added
for the CDPCho ligand can be found in Supporting infor-
mation.
The selected homology models were validated using the
PROCHECK [49], WHAT_CHECK [50] and ERRAT [51] programs
(Doc. S2, Figs S4 and S5, Tables S1 and S2). The two
homology models exhibited very similar characteristics and
differed significantly only in the presence/absence of the
Plasmodia lineage-specific, lysine-rich segment. The models
indicated that this insert lay reasonably far away from the
protein domain that harbours the active site of the con-
structs; thus it is unlikely to have a major influence on the
binding of the CDPCho ligand. Based on this and on the
results of disorder predictions the homology model of
PfCCT MDK protein was chosen for modelling the active
site of PfCCT with ligands.
Cloning and mutagenesis
The PfCCT cDNA sequence (PF3D7_1316600) was codon-
optimized for expression in E. coli (GenScript). The DNA
fragment corresponding to residues 528–795 of PfCCT was
cloned into the expression vector pET15b (Novagen) using
the NheI/BamHI sites for production of N-terminal 69
His-tagged protein. Site-directed mutagenesis to produce
the MDK (528–795, D720–737) construct of PfCCT lacking
the lysine-rich Plasmodium-specific segment (720–737) and
its W692Y and W743H point mutants was performed by
the Quickchange method (Agilent) (mutagenesis primers
are shown in Table S3). All constructs were verified by
DNA sequencing.
Protein expression and purification
The recombinant His-tagged PfCCT MDK (528–795,
D720–737) protein was expressed using the BL21 (DE3)
Rosetta E. coli expression system. Briefly, 0.5 L of LB
medium was inoculated with Rosetta cells from a 5 mL
overnight culture and grown at 37 °C until A600 reached
0.4. After 30 min cooling at 20 °C, protein expression was
induced by 0.5 mM isopropyl thiogalactoside for 20 h at
20 °C. The cells were harvested by centrifugation at 4000 g
for 20 min and stored at 80 °C. Thawed cells were resus-
pended in 30 mL of 20 mM Hepes pH 7.5, 100 mM NaCl,
1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100,
3 lgmL1 RNase, 3 lgmL1 DNase, EDTA containing
protease inhibitor cocktail tablet (Roche), 1 mM benzami-
dine and 10 mM b-mercaptoethanol. The solution was soni-
cated and centrifuged, and then the supernatant was
supplemented with 1.5 mM Mg2+ to form a chelate com-
plex with EDTA present and was applied onto a pre-equili-
brated benchtop nickel-nitrilotriacetic acid-agarose affinity-
chromatography column (Qiagen). The protein was eluted
with Hepes 20 mM, NaCl 100 mM (pH 7.5) (buffer A) con-
taining 250 mM imidazole. The eluted samples were dialy-
sed overnight in buffer A and the next day the sample was
concentrated and further purified on a HiLoad XK-16 Su-
perdex 200 column (GE Healthcare) previously equilibrated
with buffer A. The purified sample was shown to be over
90% homogeneous based on SDS/PAGE analysis, concen-
trated to 10 mgmL1 by using an ultrafiltration membrane
(Sartorius), then supplemented with 10% glycerol, and
finally flash-frozen in liquid N2 in aliquots and stored at
80 °C.
SDS/PAGE analysis of the purification procedure is
shown in Fig. 4A. Protein concentration is in monomers
throughout the whole paper. It was determined spectropho-
tometrically from the absorbance at 280 nm by using an
extinction coefficient of 31 400 M1cm1 calculated on the
basis of amino acid composition by using the PROTPARAM
server [52] and a molecular weight of 30 898 for the His-
tagged monomer (throughout the present study, molar con-
centrations of the CCT protein construct refer to the
monomer). Absorbance measurements were carried out
using a Nanodrop spectrophotometer. Protein samples were
identified by mass spectrometric analysis of the tryptic
digest on an LCQ-Fleet Ion Trap LC/MS.
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Differential scanning fluorimetry
Solutions of 59 Sypro Orange and 0.5 mgmL1 protein
were prepared in a final volume of 25 lL in 96-well PCR
plates. The plates were sealed with adhesive PCR film
(Thermo Scientific) and heated in a Stratagene Mx3000P
real-time PCR instrument (Agilent) from 25 to 85 °C in
increments of 0.5 °C. Three parallels were set up for each
condition. To obtain the midpoint of the protein melting
transition defined as a melting temperature Tm, a Boltzmann
model (Eqn 1) was used to fit the fluorescence data using
ORIGINPRO 8 (OriginLab Corp, Northampton, MA, USA).
FT ¼ F0 þ F1  F0
1þ exp ðTm  TÞ=dT (1)
where FT is the fluorescence intensity at temperature T, Tm
is the melting temperature, and F0 and F1 are the pre-tran-
sitional and post-transitional fluorescence intensities,
respectively. Data points after the fluorescence intensity
maximum F1 were excluded from fitting.
Mass spectometry
In the mass spectrometric study of protein complexes, a
commercial Waters QTOF Premier instrument equipped
with electrospray ionization source was used in the positive
ion mode. Mass spectra were obtained under native condi-
tions: namely, the ions were generated from aqueous 20 mM
NH4HCO3 buffer solution (pH 7.8) containing the PfCCT
MDK protein at 40 lM monomer concentration. These
conditions allow transfer of the native protein complex
present in the solution into the gas phase. The capillary
voltage was 2800 V, the sampling cone voltage was 128 V
and the temperature of the source was kept at 90 °C. Mass
spectra were recorded in the mass range 1500–8000 m/z.
Fluorescence spectroscopy
Emission curves were recorded on a Jobin Yvon SpeX Flu-
oromax-3 spectrofluorometer using 10-mm path length
20 °C thermostatted cuvettes with excitation at 295 nm (slit
1 nm), emission between 320 and 400 nm (slit 5 nm). 3 lM
of protein in buffer A was titrated with addition of 1–2 lL
aliquots from concentrated stock ligand solutions. After
3 min incubation, three emission scans were recorded and
then averaged. The emission maximum was determined by
fitting the upper 20% fluorescence intensity of the emission
curves with the Gauss distribution equation:
y ¼ y0 þ A exp½ðk kmaxÞ2=2x2 (2)
where k is the wavelength in nanometers and kmax is the
calculated emission peak maximum in nanometers.
The dissociation constant of ligand binding was calcu-
lated by fitting to the calculated emission shift data with a
quadratic equation (Eqn 3) as previously described [53–55]:
y ¼ A½ðcþ Kþ xÞ  ½ðcþ Kþ xÞ2  4cx0:5=2c (3)
where x is the ligand concentration (lM), y is the shift in
emission on ligand addition (nm), A is the emission shift
observed at saturation, c is the enzyme concentration (lM)
and K is the dissociation constant (lM).
Steady-state kinetic assay
A continuous coupled enzyme activity assay was employed
based on [29]. The assay was performed in 10-mm path
length 20 °C thermostatted cuvettes in a dual wavelength
Specord 200 spectrophotometer, with a reaction volume of
600 lL. Enzyme and substrate concentrations were set such
that CCT catalysis was the rate limiting step:
[MDK] = 0.16 lM, [inorganic pyrophosphatase] =
2.08 UmL1, [purine nucleoside phosphorylase] =
2.08 UmL1, [Mg2+] = 5 mM, [MESG] = 0.33 mM, and
variable concentrations of phosphocholine and CTP sub-
strates in buffer A. The reaction was started by a final
quick addition of PfCCT MDK to the reaction mixture.
Initial velocity was determined from the slope of the first
10% of the progress curve. For CTP substrate titrations,
CTP concentration was varied between 12 lM and 1.2 mM
while ChoP concentration was kept at 5 mM. For ChoP
substrate titrations, ChoP concentration was varied
between 0.2 and 20 mM while CTP concentration was kept
at 1 mM. Kinetic data were fitted with Eqns (4) and (5)
(Michaelis–Menten equation and substrate inhibition equa-
tion, respectively):
v ¼ Vmax½S
KM þ ½S (4)
v ¼ Vmax
1þ KM=½S þ ½S=Ki (5)
In these equations, v is the reaction rate (s1), Vmax is
the maximum velocity of the reaction (s1lM1), [S] is the
concentration of the substrate (lM) and Ki describes the
binding of a substrate molecule to the enzyme (lM), with
the result being a decrease by half in the rate of the reac-
tion.
Product inhibition kinetic measurements
Product inhibition studies were performed using the above
assay with CDPCho as inhibitor present in 0, 40 and
100 lM concentrations. Substrate concentration was varied
in the presence of a fixed saturating concentration of the
other substrate. The inhibition constant Ki was calculated
by global fit of the CTP titration at saturated ChoP con-
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centration curves with Eqn (6) describing full competitive
inhibition:
v ¼ Vmax=½1þ ðKM=½SÞð1þ ½I=KiÞ (6)
ITC measurements
Calorimetric measurements were performed on a MicroCal-
ITC 200 titration calorimeter (GE Healthcare) at 20 °C.
The protein samples were dialysed against buffer A, includ-
ing 10 mM b-mercaptoethanol or 0.5 mM TCEP (tris (2-car-
boxyethyl)phosphine) as reducing agent and 5 mM Mg2+
or 0.5 mM EDTA as indicated. Ligands were freshly dis-
solved in dialysis buffer and subsequently pH was adjusted,
prior to ITC measurements.
CTP and CDPCho concentrations were determined using
molar extinction coefficients 9000 M1cm1 at 271 nm, pH
7.0, and 5000 M1cm1 at 260 nm, respectively. In the
experimental setup, the cell of the instrument was filled
with protein and the syringe with the respective ligand.
Each titration typically included 27 steps of injection with
1.5 lL of ligand per injection spaced 180 s apart from each
other, with the injection syringe rotating at 500 r.p.m.
In the case of displacement ligand titrations, the enzyme
previously titrated with ChoP, reaching a final concentra-
tion of 2–5 mM, was immediately further titrated with
CDPCho. The data were analysed using MICROCAL ORIGIN
software, following the directions of the manufacturer, in
order to calculate the thermodynamic parameters: dissocia-
tion constant (Kd), stoichiometry (N), enthalpy (DH) and
entropy (DS). The heats of dilution obtained from titration
of the same ligand solutions into buffer were subtracted
from the titration data before the data were fitted to the
appropriate model.
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